This segment focuses on the development and commercialization of precision medicines for genetically-defined cancers. Research and development activities include identifying and targeting specific genomic alterations that activate the mTOR pathway. Technologies employed include protein-bound sirolimus (FYARRO) and potentially other targeted therapies. The primary therapeutic area is oncology, specifically targeting advanced malignant PEComa. The patient impact is improved outcomes and addressing unmet needs in cancer treatment. Market positioning is as a pioneer in precision oncology. Future opportunities include expanding the use of FYARRO and developing new therapies for other cancers. Clinical trials and regulatory aspects are crucial for drug approval and market access. Partnerships with next-generation sequencing leaders are key for identifying patients with relevant genomic alterations.

This segment focuses on the development of Antibody-Drug Conjugates (ADCs) through the recent transformation into Whitehawk Therapeutics. Research and development activities include in-licensing and developing a portfolio of novel ADCs. Technologies and methodologies include advanced ADC technologies. The therapeutic areas covered include oncology, with a focus on applying advanced technologies to established tumor targets. The patient impact is the potential for more effective and targeted cancer treatments. Market positioning is evolving into an ADC company. Future opportunities include expanding the ADC portfolio and advancing clinical trials. Regulatory and clinical aspects are critical for ADC development and approval. Partnerships and collaborations are essential for ADC development and commercialization.